Tenders Are Invited For Pharmaceutical Products - Conclusion Of Non-Exclusive Discount Agreements In Accorda ... in Germany

Work Detail

Pharmaceutical Products - Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V By Means Of An Open House Model For The Active Ingredient Epoetin Alfa (Genetically Engineered Human Erythropoietin - Limitation To Packs With A Dosage Of Up To 10,000 Iu). Announcement Of Changes: With The Announcement Of May 31, 2024 (322308-2024), The Open House Procedure For The Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Drugs With The Active Ingredient Epoetin Alfa (Genetically Engineered Human Erythropoietin - Restriction To Packs With Doses Up To 10,000 Iu) Was Started With A Term Of Published August 1St, 2026 To July 31St, 2026. This Announcement Announces The Early Termination Of This Open House Procedure. Due To New Requirements Regarding The Interchangeability Of Biotechnological Drugs In Public Pharmacies, This Open House Procedure Will End On May 31, 2026. All Discount Agreements Concluded In This Process Will Be Terminated At This Time. An Open House Procedure Adapted To The New Exchange Regulations Has Already Been Published In The Supplement To The Official Journal Of The Eu.

Contact Information